Neoprobe files RIGScan for European Union approval:
This article was originally published in Clinica
Executive Summary
Neoprobe has filed its colorectal cancer detection agent, RIGScan, for European approval. Neoprobe, which is based in Dublin, Ohio, has filed dossiers with the European Agency for the Evaluation of Medicinal Products and rapporteur reviewers in Denmark and the UK. An application to the US FDA is planned for late this summer.